SMYD3 and colorectal carcinoma: The generation of an oxaliplatin-resistant CRC cell line and the analysis of patients’ residual gastric or rectal tumors that were resected after neoadjuvant therapy revealed a significant increase in SMYD3 protein levels in resistant samples.